Insider trading

Period: 120 months Stock: DXCM + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

605 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

605 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

605 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

605 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
605 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
605 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

605 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
13 Aug 2018
SAYER KEVIN R President, CEO & Chairman
Sold, plan not stated 3×
$1.38M 11,161 at 123.22
3.2%
10 Aug 2018
Murphy Patrick Michael VP, Legal Aff & Chf Compl Ofcr
Sold, plan not stated 4×
$1.55M 12,500 at 124.18
27.1%
6 Aug 2018
Sold, plan not stated 2×
$1.10M 9,070 at 121.18
53.8%
Sold half or more
6 Aug 2018
AUGUSTINOS NICHOLAS Director · indirect
Sold, plan not stated
$393.30K 3,230 at 121.77
18.4%
1 Aug 2018
MOY JEFFREY SVP, Operations · indirect
Sold, plan not stated
$548.87K 5,831 at 94.13
53.5%
Sold half or more
25 Jul 2018
Pacelli Steven Robert EVP, Strategy & Corp. Dev.
Sold, plan not stated 2×
$317.33K 3,114 at 101.91
2.4%
23 Jul 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated 2×
$264.51K 2,581 at 102.48
70.8%
Sold half or more
16 Jul 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated 3×
$995.56K 10,000 at 99.56
16.4%
16 Jul 2018
Balo Andrew K EVP, Reg. Strategy, Clinical
Sold, plan not stated 3×
$497.82K 5,000 at 99.56
4.6%
9 Jul 2018
SAYER KEVIN R President & CEO
Sold, plan not stated 3×
$1.42M 14,219 at 99.79
4.1%
28 Jun 2018
MOY JEFFREY SVP, Operations · indirect
Sold, plan not stated 3×
$5.47M 59,193 at 92.48
84.5%
Sold half or more
25 Jun 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$254.43K 2,581 at 98.58
41.4%
15 Jun 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated
$978.10K 10,000 at 97.81
91.9%
Sold half or more
12 Jun 2018
TOPOL ERIC Director · indirect
Sold, plan not stated
$2.00M 20,000 at 100.10
19.1%
23 May 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$221.96K 2,581 at 86.00
29.3%
15 May 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated
$858.97K 10,000 at 85.90
91.9%
Sold half or more
14 May 2018
SKYLER JAY S Director · indirect
Sold, plan not stated
$2.64M 30,000 at 88.00
57.4%
Sold half or more
9 May 2018
SAYER KEVIN R President & CEO
Sold, plan not stated
$1.45M 17,245 at 84.37
4.7%
9 May 2018
Leach Jacob Steven SVP, Research & Development
Sold, plan not stated 2×
$741.33K 8,745 at 84.77
8.1%
8 May 2018
SKYLER JAY S Director · indirect
Sold, plan not stated
$2.68M 31,464 at 85.11
58.6%
Sold half or more
8 May 2018
Leach Jacob Steven SVP, Research & Development · indirect
Sold, plan not stated
$212.87K 2,500 at 85.15
5.0%
8 May 2018
Leach Jacob Steven SVP, Research & Development
Sold, plan not stated
$163.37K 1,923 at 84.95
1.9%
23 Apr 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$188.65K 2,581 at 73.09
22.7%
16 Apr 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated
$730.41K 10,000 at 73.04
91.9%
Sold half or more
23 Mar 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$176.64K 2,581 at 68.44
18.5%
15 Mar 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated
$655.12K 10,000 at 65.51
47.9%
23 Feb 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$92.25K 1,638 at 56.32
10.5%
15 Feb 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated
$559.10K 10,000 at 55.91
32.4%
23 Jan 2018
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$89.38K 1,635 at 54.67
9.5%
16 Jan 2018
GREGG TERRANCE H Executive Chairman · indirect
Sold, plan not stated
$568.59K 10,000 at 56.86
24.5%
26 Dec 2017
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$92.20K 1,635 at 56.39
8.7%
12 Dec 2017
SAYER KEVIN R President & CEO
Sold, plan not stated
$353.09K 6,000 at 58.85
2.1%
11 Dec 2017
Balo Andrew K EVP, Reg. Strategy, Clinical
Sold, plan not stated
$198.69K 3,245 at 61.23
3.9%
29 Nov 2017
Balo Andrew K EVP, Reg. Strategy, Clinical
Sold, plan not stated
$389.40K 6,490 at 60.00
7.3%
29 Nov 2017
Pacelli Steven Robert EVP, Strategy & Corp. Dev.
Sold, plan not stated
$174.34K 2,900 at 60.12
2.9%
27 Nov 2017
FOLETTA MARK G Director · indirect
Sold, plan not stated
$137.39K 2,500 at 54.95
16.0%
24 Nov 2017
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$90.79K 1,635 at 55.53
8.0%
20 Nov 2017
SAYER KEVIN R President & CEO
Sold, plan not stated
$660.00K 12,000 at 55.00
4.0%
20 Nov 2017
KAHN BARBARA Director · indirect
Sold, plan not stated
$163.73K 3,000 at 54.58
11.5%
7 Nov 2017
ALTMAN STEVEN R Director · indirect
Bought
$1.25M 25,000 at 50.01
74.6%
First buy on file
6 Nov 2017
ALTMAN STEVEN R Director · indirect
Bought
$496.10K 10,000 at 49.61
42.5%
First buy on file
23 Oct 2017
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$73.27K 1,635 at 44.82
7.4%
25 Sep 2017
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$114.08K 1,635 at 69.77
6.9%
25 Sep 2017
Pacelli Steven Robert EVP, Strategy & Corp. Dev.
Sold, plan not stated
$101.22K 1,450 at 69.81
1.4%
20 Sep 2017
SAYER KEVIN R President & CEO
Sold, plan not stated
$416.04K 6,000 at 69.34
2.0%
11 Sep 2017
Balo Andrew K EVP, Reg. Strategy, Clinical
Sold, plan not stated
$234.44K 3,244 at 72.27
3.2%
23 Aug 2017
Pacelli Steven Robert EVP, Strategy & Corp. Dev.
Sold, plan not stated
$300.04K 3,987 at 75.26
3.6%
23 Aug 2017
DOUBLEDAY RICHARD EVP, Chief Commercial Officer · indirect
Sold, plan not stated
$123.05K 1,635 at 75.26
6.4%
11 Aug 2017
SAYER KEVIN R President & CEO
Sold, plan not stated
$418.64K 6,000 at 69.77
1.8%
10 Aug 2017
Balo Andrew K EVP, Reg. Strategy, Clinical
Sold, plan not stated
$230.92K 3,244 at 71.18
3.1%
Showing 501–550 of 605. ← Newer Page 11 of 13 Older →